However, virus activity was significantly prolonged in VSV-GP-Luc treated LLC1-IFNAR1−/− tumours (Fig. 4e) compared to the duration of virus replication in C57BL/6J mice, supporting the earlier findings of relapse-free long-term therapeutic outcome of VSV-GP treatment in immune-compromised hosts. Here, IFNAR1 is linked to neoplasm.